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Abstract
Human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/
AIDS) is a disease pertained to the human immune system. Given its crucial role in viral 
replication, HIV-1 protease (HIV-1 PR) is a prime therapeutic target in AIDS therapy. In this 
regard, the dynamic aspects of ligand-enzyme interactions may indicate an important role of 
conformational variability in HIV-1 PR inhibitor/drug design. In the present contribution, the 
effect of HIV-1 PR flexibility (within multiple crystallographic structures of HIV-1 PR) on 
binding to the Amprenavir was elucidated via an ensemble docking approach. Molecular docking 
studies were performed via advanced AutoDock4.2 software. Ensemble docking of Amprenavir 
into the active site of various conformations of HIV-1 PR predicted different interaction modes/
energies. Analysis of binding factors in terms of docking false negatives/positives revealed 
a determinant role of enzyme conformational variation in prediction of optimum induced fit 
(PDB ID: 1HPV). The outcomes of this study demonstrated that conformation of receptor may 
significantly affect the accuracy of docking/binding results in structure-based rational design 
of anti HIV-1 PR agents. Furthermore; some strategies to re-score the docking results in HIV-1 
PR targeted docking studies were proposed.
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Introduction
Acquired immunodeficiency syndrome (AIDS) 
is a disease related to the human immune system 
(1). Human immunodeficiency virus (HIV) has 
been identified as the etiological agent of AIDS 
(2). Cells of the immune system, called T-cells 
or CD4 cells that are responsible for fighting 
against infections and other physiological 
disturbances are attacked and destroyed by 
HIV. One of the essential HIV enzymes, whose 
activity is necessary for viral replication, is HIV-
1 protease (HIV-1 PR) (3). In fact, production of 
mature and infectious viral particles is depended 
on the proteolytic activity of the HIV-1 PR and 
for this reason; this enzyme was recognized as 
a major therapeutic target in AIDS therapy and 
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structures of HIV-1 proteases (17, 18). 
Amprenavir (Figure 1) is a potent and selective 
HIV-1 PR inhibitor with sub-nanomolar HIV-1 
PR inhibition activity (ki=0.6 nM) (19, 20) and 
hence was selected as a model in our studies. 
Experimental
Materials and methods
All the required holo/apo PDB structures were 
retrieved from the Brookhaven protein databank 
(http://www.rcsb.org). Flexible-ligand docking 
studies were performed using AutoDock4.2 
program (21). All 3D structures of ligands were 
prepared using CORINA server (http://www.
molecular-networks.com/). The pre-processing 
steps for receptor crystallographic files (PDB 
codes: 2PQZ, 2Q5K, 3EKV, 3MXD, 3O9F, 
3O9I, 3SA5, 3SA8, 3SAB, 4DJP, 4DQB, 2PSU, 
2Q54, 3EKX, 3MXE, 3O9G, 3SA3, 3SA6, 
3SA9, 3SAC, 4DJQ, 2PSV, 2Q55, 3EM3, 3NLS, 
3O9H, 3SA4, 3SA7, 3SAA, 4DJO, 4DJR, 1AJV, 
1BWA, 1CPI, 1HPV, 1T3R, 1XL5, 1A8G, 
1A9M, 1BWB, 1AJX, 1BV9, 1DIF, 1GNO, 
1IDB, 1MUI, 1T7J, 1XL2, 2I0A, 2I0D and 
3IXO) were performed within AutoDock Tools 
1.5.4 program (ADT) and WHAT IF server 
(http://swift.cmbi.ru.nl/servers/html/) (21, 22). 
The 3D structure of HIV-1 PR enzyme with the 
code 1HPV (including Amprenavir ligand) was 
used as a reference point in our docking studies. 
All hydrogens were properly added to the 
receptor PDB files using WHAT IF server. ADT 
program was used to merge non-polar hydrogens 
has been the subject of numerous drug design 
studies (4, 5). 
HIV-1 PR inhibitors are believed to inactivate 
the HIV-1 protease leading to the immature, 
non-infectious viral particles (6). Most of 
the developed HIV-1 protease inhibitors are 
peptidomimetic molecules (7). The main 
drawback of peptidomimetic compounds is 
their low oral bioavailability arising from high 
molecular weight and poor solubility (8). Due to 
this limitation, many researchers have focused on 
nonpeptidic HIV-1 PR inhibitors (3, 9, 10).
Amprenavir, Atazanavir, Darunavir, Indinavir, 
Fosamprenavir, Lopinavir, Nelfinavir, Ritonavir, 
Saquinavir and Tipranavir are typical anti-AIDS 
drugs that have been approved by the United States 
Food and Drug Administration (US FDA) as HIV-
1 PR inhibitors. These drugs are currently used 
in combination therapy with reverse transcriptase 
inhibitors (11, 12). Although several successful 
drugs have been developed against AIDS, current 
status shows a rapid emergence of drug resistance 
to most of the HIV-1 PR inhibitors (11). In this 
regard, recent research aimed at proposing 
new anti-protease agents with minimum side 
effects and being able to delay the appearance of 
resistance (13, 14).
In continuation to our interest in structure 
based modeling of bioactive molecules (15, 16) 
and to further elucidate the important role of 
target conformation in molecular docking results, 
we decided to explore the significance of HIV-
1 PR flexibility through ensemble docking of 
Amprenavir into the multiple crystallographic 
Figure 1. Chemical structure of Amprenavir.
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into related carbon atoms of the receptor and 
Kollman charges were also assigned. For docked 
ligands, non-polar hydrogens were merged; 
Gasteiger charges assigned and torsions degrees 
of freedom were also allocated by ADT program. 
100 independent genetic algorithm (GA) runs 
were considered. 2.5×107 maximum number 
of evaluations was used for Lamarckian GA 
method. All other docking parameters were set at 
their default values. A grid of 60×60×60 points 
in x, y, and z direction was built centered on the 
center of mass of the catalytic site of HIV-1 PR 
crystallographic structures. Cluster analysis was 
performed on the docked results using a root 
mean square (RMS) tolerance of 2 A˚. 
Schematic 2D representations of the ligand-
receptor interactions were all generated using 
LIGPLOT (23).
Results 
Docking validation
A performance of a docking simulation 
method was checked via its ability in 
reproducing a binding mode for a co-
crystallographic (cognate) ligand (24). For 
this purpose, the structure of a cognate ligand 
(Amprenavir) was retrieved and re-docked 
into the active site of HIV-1 PR structures. 
Root mean square deviations (RMSD) of the 
Cartesian coordinates of the re-docked ligand 
atoms proved the validation of docking method 
for further modeling studies (Table 1) (25). As 
it is obvious from the summarized data, all the 
crystallographic files under study represented 
adaptable predictability level (26) within 100 
independent genetic algorithm (GA) runs and 
2.5×107 maximum number of evaluations for 
Lamarckian GA method. It should be noted that 
those structures exhibiting RMSD values over 3 
may also pass the filter when considering their 
number of active torsions (27).
Ensemble docking of Amprenavir
We aimed to evaluate the Amprenavir / HIV-
1 PR interaction considering ligand induced 
enzyme conformation. Our dataset included one 
apo and fifty holo HIV-1 PR structures. These 
structures were subjected to ensemble docking 
procedure. Crystallographic structure of the 
Amprenavir/HIV-1 PR complex was deposited in 
the PDB website (1HPV) (28) and as mentioned 
before, this crystallographic structure was 
considered as the reference point in our docking 
simulations. 
The RMSD of the backbone carbon atoms 
(Cα) in the selected PDB structures ranged 
0.22–0.85 and 0.24-0.93 Å in chains A and B of 
HIV-1 PR, respectively (with regard to the PDB 
code: IHPV; Figure 2). Different RMSD values 
indicated the conformational changes of HIV-1 
PR upon binding to the various inhibitors.
Amprenavir/HIV-1 PR interactions  
Lipophilic contacts (Figure 4) and H-bond 
interactions (Table 3) in docked Amprenavir-
protease complexes were monitored. According 
to the 2D Ligplot diagrams, thirty-two residues 
of the HIV-1 PR were found to make lipophilic 
contacts with Amprenavir within fifty-one 
enzyme conformational structures. In the case of 
hydrogen bond interactions, a total of nineteen 
amino acids interacted Amprenavir within 
51 conformations of the enzyme. Data are 
summarized in Table 3 while numbers refer to 
the H-bond distances.
Validation of virtual binding affinities
To further validate the AutoDock binding 
affinities, two co-crystallographic HIV-1 PR/
inhibitor datasets with available biological 
activities at PDB bind (29) (Figure 5) or Binding 
MOAD (30) (Figure 6) databases were selected 
for a regression analysis. AutoDock binding 
affinities were all obtained from the self-docking 
step.
Effective factors in binding conformation 
We were interested in finding the factors that 
might be determinant in induced conformation 
of HIV-1 PR/Amprenavir complex (PDB ID: 
1HPV). For these purpose; a binding system 
comprised of three major constituents (ligand, 
enzyme and their interaction) was taken into 
consideration. Such a system may be defined by 
several descriptors that are related to the system 
constituents (Figure 7).
To account for the conformational deviation 
of HIV-1 PR from its apo structure (native 
conformation), a pair wise structure alignment 
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RMSD from reference structure (Å)Maximum No. of energy evaluationsGA runsPDB code
3.532.5×1071004DJO
3.172.5×1071004DJP
3.492.5×1071004DJQ
2.202.5×1071004DJR
2.732.5×1071004DQB
3.172.5×1071003SA7
2.612.5×1071003SA8
3.372.5×1071003SA9
2.362.5×1071003NLS
2.632.5×1071003O9G
3.762.5×1071003O9F
2.992.5×1071003O9H
3.052.5×1071003O9I
3.032.5×1071003SA3
2.262.5×1071003SA4
1.602.5×1071003SA5
2.342.5×1071003SA6
1.142.5×1071003SAC
3.132.5×1071002Q5K
4.162.5×1071002Q54
3.332.5×1071002Q55
2.392.5×1071003EM3
1.532.5×1071003EKV
2.302.5×1071003EKX
3.002.5×1071003MXD
2.892.5×1071003MXE
2.492.5×1071002PSV
0.342.5×1071002PQZ
2.942.5×1071002PSU
2.562.5×1071001T3R
2.972.5×1071001MUI
2.852.5×1071002I0A
2.022.5×1071001IDB
0.472.5×1071001T7J
2.912.5×1071001XL2
2.282.5×1071001XL5
3.852.5×1071001GNO
3.452.5×1071001A9M
4.452.5×1071001DIF
1.182.5×1071001AJV
0.642.5×1071001AJX
1.722.5×1071001CPI
2.062.5×1071001BWA
1.562.5×1071001BWB
2.132.5×1071001BV9
2.282.5×1071003SAB
1.002.5×1071003SAA
2.152.5×1071002I0D
1.802.5×1071001HPV
---3IXO a
Table 1. Docking validation results for different holo PDB structures of MAO-B using AutoDock4.2.
a 3IXO is an apo file.
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Figure 2. The RMSD (Ǻ) of the backbone carbon atoms (Cα) in the A) chain A of HIV-1 PR and B) chain B of HIV-1 PR structures 
with regard to the Amprenavir/HIV PR complex (PDB code: IHPV) To run the project, Amprenavir was docked into the active site of 
multiple HIV-1 PR conformations. AutoDock binding affinities and Amprenavir binding conformations (ligand binding ensembles) are 
represented in Table 2 and Figure 3, respectively. 
PDB code of the receptor AutoDock binding energy(kcal/mol) PDB code of the receptor
AutoDock binding energy
(kcal/mol)
1A8G -7.28 3EKX -7.95
1A9M -8.30 3EM3 -8.90
1AJV -7.77 3MXD -7.86
1AJX -7.24 3MXE -7.66
1BV9 -7.38 3NLS -8.24
1BWA -9.25 3O9F -8.42
1BWB -8.67 3O9H -7.81
1CPI -7.41 3O9I -7.59
1DIF -6.64 3O9G -7.37
1GNO -8.60 3SA3 -7.90
1HPV -7.83 3SA4 -7.92
1IDB -6.90 3SA5 -7.97
1MUI -7.09 3SA6 -7.72
1T3R -8.11 3SA7 -7.51
1T7J -7.45 3SA8 -8.11
1XL2 -6.73 3SA9 -7.87
1XL5 -7.60 3SAA -9.15
2I0A -7.88 3SAB -8.16
2I0D -7.37 3SAC -8.06
2PQZ -7.32 4DJO -7.85
2PSU -7.66 4DJP -7.46
2PSV -8.12 4DJQ -7.79
2Q5K -8.00 4DJR -7.67
2Q54 -8.19 4DQB -7.85
2Q55 -7.33 3IXO -4.94
3EKV -8.10
Table 2. AutoDock binding affinities of Amprenavir/HIV-1 PR complexes.
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Figure 3. Amprenavir binding ensembles as the result of docking into the different conformations  
of the HIV-1 PR; each conformation of the target is designated by its relevant PDB code.
was done. RMSD (Ǻ) of the backbone carbon 
atoms (Cα) in the chain A of individual 
HIV-1 PR structures with regard to the HIV PR 
apo structure (PDB ID: 3IXO) are reported in 
Table 4.
Analysis of binding results via docking false 
negative/positives
Ensemble docking approach may be 
interpreted in terms of predicted false negative 
(FN)/false positive (FP) results. High rate of 
false negatives/positives is a common issue in 
docking procedure leading to low “hit rates”. 
Due to this rationale, we decided to evaluate the 
docking results (Table 4) via FP and FN results.
For the sake of clarity, estimated descriptors 
(binding factors) for Amprenavir/HIV-1 PR 
co-crystallographic complex (IHPV) were 
considered as reference points in our analysis. 
In this manner, two distinct regions may be 
considered for each binding factor; a distance 
between reference level and optimum level 
including FPs and a distance between reference 
level and non-optimum level including FNs 
(Figure 8). 
Discussion
Ensemble docking approach
Docking is a popular virtual structure-based 
method that is used in the design of biologically 
interesting molecules (31). It enables the 
HIV-1 PR Flexibility in Molecular Docking
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Table 3. Possible H-bond interactions of Amprenavir with different conformations of the HIV-1 PR.
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Table 3. Continue.
 
 
Figure 4. 2D fingerprint representation of lipophilic contacts in binding of Amprenavir to the HIV-1 PR ensembles. (Red: interacted; 
Green: Non-interacted).
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Figure 5. Correlation of AutoDock binding affinities and biological activities (PDB bind database) for a series of co-crystallographic 
HIV-1 PR inhibitors (PDB codes: 4DJO, 4DJP, 4DJQ, 4DJR, 2Q5K, 3MXD, 3MXE, 2PSV, 2PQZ, 2PSU, 2I0A, 1GNO, 1A9M, 1AJV, 
1AJX, 1BWA, 1BV9, 2I0D).
Figure 6. Correlation of AutoDock binding affinities and biological activities (Binding MOAD database) for a series of co-crystallographic 
HIV-1 PR inhibitors (PDB codes: 4DJO, 4DJP, 4DJQ, 4DJR, 2Q5K, 2Q5S, 3MXD, 3MXE, 2PSV, 2PQZ, 2PSU, 1T3R, 2I0A, 1XL2, 
1XL5, 1GNO, 1A9M, 1AJV, 1AJX, 1BWA, 1BV9, 2I0D). 
 
 Figure 7. Schematic representation of the ligand-enzyme binding system and its related descriptors, system constituents in our study 
are ligand (Amprenavir), enzyme (HIV-1 PR) and their interaction. System descriptors are AutoDock score, protein deviation from apo 
form, number of lipophilic interacted residues, number of H-bond interactions and instability energy of ligand binding pose (∆E
instability
). 
∆E
instability 
indicates the instability gain of geometrically optimum conformation as the result of binding to the receptor (19).
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Code of docked 
HIV-1 PR file
AutoDock binding 
affinity
(kcal/mol)
Number of 
lipophilic interacted 
residues
Number of  
H-bond 
interactions
RMSD from reference 
structure b 
(kcal/mol)
∆Einstability 
c of docked ligand 
conformation 
(kcal/mol)
2PQZ -7.32 17 3 0.70 74.63
2Q5K -8.00 18 5 0.57 47.69
3EKV -8.10 21 3 0.53 69.81
3MXD -7.86 19 3 0.49 83.93
3O9F -8.42 19 3 0.56 65.42
3O9I -7.59 17 3 0.49 65.56
3SA5 -7.97 15 4 0.52 80.89
3SA8 -8.11 14 5 0.55 41.07
3SAB -8.16 11 6 0.54 73.27
4DJP -7.46 16 4 0.49 67.26
4DQB -7.85 19 4 0.57 66.53
2PSU -7.66 18 4 0.50 71.54
2Q54 -8.19 15 6 0.51 64.30
3EKX -7.95 21 4 0.60 75.94
3MXE -7.66 14 4 0.55 76.66
3O9G -7.37 16 4 0.57 81.69
3SA3 -7.90 16 4 0.52 69.02
3SA6 -7.72 16 4 0.55 71.66
3SA9 -7.87 14 6 0.51 96.32
3SAC -8.06 18 3 0.54 74.84
4DJQ -7.79 13 5 0.52 89.37
2PSV -8.12 23 2 0.48 75.17
2Q55 -7.33 23 1 0.54 86.89
3EM3 -8.90 17 6 0.52 76.43
3NLS -8.24 18 4 0.69 84.52
3O9H -7.81 17 6 0.48 75.92
3SA4 -7.92 16 5 0.54 68.09
3SA7 -7.51 15 3 0.53 72.84
3SAA -9.15 19 2 0.56 71.18
4DJO -7.85 16 5 0.48 70.58
4DJR -7.67 14 4 0.47 99.29
1AJV -7.77 20 2 0.59 80.68
1BWA -9.25 17 2 0.43 82.76
1CPI -7.41 14 4 0.49 93.63
1HPV a -7.83 19 4 0.38 88.07
1T3R -8.11 19 4 0.49 68.50
1XL5 -7.60 18 4 0.69 81.04
1A8G -7.28 18 3 0.40 97.52
1A9M -8.30 18 6 0.65 72.82
1BWB -8.67 15 1 0.40 75.10
1AJX -7.24 15 5 0.56 89.08
1BV9 -7.38 15 4 0.46 66.60
1DIF -6.64 18 3 0.47 85.69
1GNO -8.60 20 4 0.41 109.50
1IDB -6.90 14 2 0.80 82.72
1MUI -7.09 17 3 0.47 65.69
1T7J -7.45 13 4 0.52 21.84
1XL2 -6.73 14 2 0.87 75.61
2I0A -7.88 20 4 0.53 63.65
2I0D -7.37 16 5 0.55 67.98
Table 4. Estimated binding factors for various docked Amprenavir/HIV-1 PR systems.
a Crystallographic system comprising Amprenavir and HIV-1 PR
b Reference structure is the apo form of HIV-1 PR (PDB code: 3IXO). 
c ∆E instability = Etop-ranked docked – Eoptimized conformation
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Figure 8. Number of false negative (FN) and false positive (FP) 
results for the estimated binding factors of docked Amprenavir/
HIV-1 PR complexes; left side digits indicate optimum levels 
(except for b and c), center digits show the estimated value for 
Amprenavir/HIV-1 PR co-crystallographic complex, right side 
digits indicate non-optimum levels (except for a, d and e).
prediction of stereoelectronic complementary 
fit of a potential bioactive ligand with its 
biomolecular target. In this regard; availability of 
crystallographic data on HIV-1 PR (Brookhaven 
protein databank website: http://www.rcsb.
org) facilitated the performance of structure 
based drug discovery projects aiming at 
HIV-1 PR as a biomolecular target for AIDS 
disease. 
The HIV-1 PR consists of two identical 99 
amino acid monomers representing a homodimer 
with C2 symmetry. Each subunit includes one 
of the two conserved triads (Asp-Thr-Gly) 
containing the catalytically active aspartate 
residues; Asp 25 and Asp 25′ (32). It has been 
well known that upon binding of different HIV-
1 PR inhibitors, significant conformational 
changes might be expected for the enzyme (33, 
34). Indeed, dynamic aspects of binding in the 
interaction of HIV-1 PR inhibitors with HIV-
1 PR active site are crucially important for the 
design of novel enzyme inhibitors. Due to the 
computational cost in designating numerous 
degrees of freedom, incorporation of meaningful 
protein flexibility during a docking procedure is 
a difficult task although several efforts have been 
performed (35).
One of the alternative approaches for the 
flexible-receptor docking is the cross-docking of 
a typical ligand into the multiple crystallographic 
structures of the receptor (protein ensemble 
structures) (21). Holo crystallographic structures 
of targets provide appropriate models that 
represent real ligand induced conformations 
upon binding to the various chemical scaffolds 
(different inhibitors). In the case of biological 
targets lacking sufficient crystallographic holo 
structures, conformational ensemble may be 
generated virtually. However the advantage of 
the latter approach would be the possibility of 
generating more protein conformations but at 
the same time, a major drawback remains; the 
produced protein conformations may not be 
indicative of real structures.  
A simple flow chart representing the ensemble 
docking procedure might be depicted as below 
(Figure 9). It should be noted that ligand binding 
ensembles (resulted from ensemble docking) 
may be subsequently exploited as valuable 
input data for quantitative structure binding 
relationship studies.
Results of ensemble docking showed that 
Amprenavir interacted with HIV-1 PR active site 
via different binding modes. None of the docked 
ligands showed completely identical binding 
poses in the active site of the HIV-1 PR and the 
best scored conformation might not be supported 
with highest binding energy (refer to Table 2). 
Amprenavir/HIV-1 PR Interactions 
The frequency of occurrence for a specific 
chemical interaction in multi-conformational 
ligand-enzyme assemblies may indicate the 
significance of such interaction in ligand-
enzyme complex. Regarding the binding data, 
some principles might be driven:
- Docked Amprenavir showed different 
hydrophobic and H-bond binding patterns in 
multiple conformational ensembles of HIV-1 PR 
active site.
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Figure 9. A typical flowchart representing an ensemble docking protocol for HIV-1 PR inhibitors.
- Docking results demonstrated that 
Asp25(A), Ile50(A), Asp25(B) and Ile50(B) 
were determinant residues contributing to 
key H-bonds (with Amprenavir) within HIV-
1 PR crystallographic ensembles. For more 
clarification, the fluctuation of H-bond lengths 
between these four residues and Amprenavir in 
the active site of HIV-1 PR ensembles is depicted 
in Figure 10. H-bond distance variations ranged 
1.78-2.70, 1.75-2.53, 1.69-2.81 and 1.82-2.49 Å 
for Asp25(A), Ile50(A), Asp25(B) and Ile50(B) 
residues, respectively.
The frequency of occurrence for lipophilic 
interactions could be prioritized as Ala28(B) > 
Glu49(B) > Ala28(A)=Glu49(A) > Ile84(B) > 
Ile84(A) > Glu48(B) > Val32(B)=Pro81(A) > 
Glu27(B) > Val82(A) > Glu48(A) > Val82(B) > 
Asp25(A)=Glu27(A) > Ile50(A) > Asp30(A) > 
Val32(A) > Ile47(B) > Pro81(B) > Asp29(A) > 
Ile47(A) > Leu23(B) > Asp25(B) > Asp30(B) > 
Ile50(B) > Thr80(A) > Asp29(B) > Leu23(A) > 
Thr80(B) > Arg8(B) > Arg8(A). Capital letters 
in the parentheses indicate the chain of HIV-1 
PR including the designated amino acid.
- On the basis of binding results, Ala28(B) 
is the most important residue contributing to 
key electrostatic interactions in nearly all of the 
Amprenavir binding poses. Such priority orders 
emphasize the effect of target conformation on 
docking results. 
- Comparison of different binding 
poses of Amprenavir revealed that the binding 
conformations represented by 2PSV and 2Q55 
PDB codes were supported by the highest 
lipophilic contacts (Figure 4). For HIV-1 PR 
induced conformation designated by the PDB 
code 3SAB, minimum lipophilic contacts could 
be detected. 
On the basis of obtained data, the contribution of 
H-bond among studied HIV-1 PR conformations 
might be prioritized as Ile50(B) > Ile50(A) > 
Asp25(A) > Asp25(B). It is also notable that 
none of the ligand binding conformations 
showed all of the four key H-bonds with HIV-
1 PR while sixteen binding poses (1T7J, 1MUI, 
1BV9, 1AJX, 1A9M, 1HPV, 2PQZ, 3O9H, 
3SAC, 3SA9, 3MXE, 3SAB, 3MXD, 4DJR and 
4DJO) interacted with three out of four residues 
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Figure 10. Fluctuation of H-bond lengths in binding of Amprenavir with Asp25(A), Ile50(A), Asp25(B) and Ile50(B) residues in HIV-1 
PR crystallographic ensembles.
simultaneously (Table 3).
Analysis of binding maps showed that hydroxyl 
group of Amprenavir contributed to the 
H-bond(s) with Asp25(A) and Asp25(B) while 
sulfonamide oxygen atoms may be involved 
in H-bond interactions with Ile50(A) and 
Ile50(B) residues of HIV-1 PR. 2D schematic 
representation of binding interactions between 
Amprenavir and HIV-1 PR structure (PDB ID: 
4DJO) is depicted in Figure 11.
Regression analysis of docking results versus 
biological data 
Our regression analysis showed that docking 
outputs could be used for the elucidation of 
HIV-1 PR inhibitory activities (PDB bind 
database) with a relatively good predictability 
level (R2=0.703; Figure 5). Our results exhibited 
a lower regression coefficient for Binding 
MOAD activities (R2=0.443; Figure 6).
Analysis of binding determinants
We decided to rank the probable determinant 
factors of the ligand induced enzyme 
conformation. In our opinion, the results 
of such study might assist in re-scoring the 
docking results within a screened dataset. 
Results of pair wise alignment study with apo 
conformation of the enzyme (3IXO) showed 
that co-crystallographic HIV-1 PR/Amprenavir 
complex (PDB ID: 1HPV) was associated with 
minimum geometrical deviation of enzyme from 
its apo structure (RMSD=0.38 Ǻ, Table 4). This 
observation confirmed the literature evidence 
that in binding to the inhibitors, a majority of 
enzymes might be necessarily redecorated via 
an optimum geometrical path (36). However, the 
most geometric deviation of the enzyme could 
be observed for the HIV-1 PR conformation 
designated by PDB code 2XL2 (RMSD=0.87 
Ǻ, Table 4). For further consideration, 2D 
schematic representation of pair wise structural 
alignments between chains A of apo HIV-1 PR 
(3IXO) and holo HIV-1 PRs (IHPV and 1XL2) 
were depicted in Figure 12. Analysis of residues 
showed that maximum distortion of HIV-1 PR 
conformation in 1XL2 structure occurred within 
a loop containing Gly48, Gly49, Ile50, Gly51, 
Gly52 and Phe53 residues (red highlighted in 
Figure 12b).
Estimated descriptors for various 
Amprenavir/HIV-1 PR systems (Table 4) were 
normalized (0-100%) to elucidate their probable 
significance in achieving the optimum target 
conformation upon binding to Amprenavir (PDB 
ID: 1HPV). For this purpose, each descriptor was 
designated by two numerical values indicating 
the optimum and non-optimum levels. In the 
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 Figure 11. 2D schematic representation of binding interactions between Amprenavir and HIV-1 PR active site (deposited PDB code: 
4DJO), green, yellow and red ovals represent H-bonds between Amprenavir and Asp25(B), Ile50(B) and Ile50(A), respectively. 
 
Figure 12. 3D schematic representation of pair wise structure alignment between apo HIV-1 PR conformation (3IXO: orange stick) and 
a) 1HPV (RMSD=0.38 Ǻ) designated by blue stick, b) 1XL2 (RMSD=0.87 Ǻ)  designated by blue stick containing a cognate ligand 
i.e., N-benzyl-2-(2,6-dimethylphenoxy)-N-[((3R,4S)-4 {[isobutyl(phenylsulfonyl) amino] methyl} pyrrolidin-3-yl)methyl] acetamide, 
the most distorted residues are highlighted by red circle in 1XL2.
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case of ∆E
instability 
of docked ligand conformation 
and RMSD of enzyme from reference structure, 
generally accepted optimum values were 0 kcal/
mol and 0 Ǻ, respectively, hence these values 
were taken as optimum levels. It should be 
noted that no commonly accepted thresholds for 
optimum scores of AutoDock binding affinity, 
number of lipophilic interacted residues and 
number of H-bond interactions in a typical 
enzyme/inhibitor system could be rationalized. 
Due to this restriction, optimum levels of these 
factors were considered as the best achieved 
scores within the docked Amprenavir/HIV-1 PR 
systems. Similarly, the lowest numerical levels of 
all descriptors were taken as the worst achieved 
scores within the docked Amprenavir/HIV-1 PR 
systems (Table 5). The probable significances 
of five descriptors in the achieved induced fit 
of Amprenavir/HIV-1 PR complex (1HPV) 
were reported as significance percentages. 
Significance values of the descriptors were all 
estimated within the optimum and non-optimum 
levels (Table 5).
Data mining showed that induced fit of 
Amprenavir/HIV-1 PR complex might be 
significantly determined by lipophilic contacts 
followed by deviation of enzyme from its native 
conformation, H-bond patterns, estimated free 
binding energy and deviation of ligand from 
its optimum conformation (designated by ∆E 
instability), respectively. Of course we believe that 
such priority order have been achieved within the 
selected dataset in this study and more extended 
explorations through larger enzyme/inhibitor 
datasets would be less biased to the size of dataset.
Descriptor Non-optimum level a
Optimum 
level b
Estimated for 
IHPV system
Significance% of the estimated 
descriptor for IHPV system
AutoDock binding affinity (kcal/mol) -6.64 -9.25 -7.83 45.6
Number of lipophilic interacted residues 11 23 19 66.7
Number of H-bond interactions 1 6 4 60
RMSD of enzyme from reference structure c (kcal/mol) 0.87 e 0 0.38 56.3
∆E
instability  
d of docked ligand conformation (kcal/mol) 109.50 f 0 88.07 21.4
Table 5. Levels of estimated factors for induced conformations of HIV-1 PR.
  a The worst achieved scores within the docked Amprenavir/HIV-1 PR systems (Table 4)
  b The best achieved scores within the docked Amprenavir/HIV-1 PR systems (Table 4) except for last two records that are the generally 
accepted best scores.
 c Reference structure is the apo form of HIV-1 PR (PDB code: 3IXO). 
 d ∆E instability = Etop-ranked docked – Eoptimized conformation
e, f Minimum level of these two descriptors is not translated into the lowest level, but it means the most inappropriate condition.
FP and FN
Analysis of binding factors exhibited that 
none of the Amprenavir conformations could be 
recognized as FP points on the basis of factor d 
(conformational variation of enzyme from apo 
structure). This observation is very important and 
emphasizes on the determinant role of enzyme 
conformational variation in prediction of ligand 
induced binding poses. Further investigations via 
chemically diverse inhibitors may be possibly 
the subject of future investigations in this field. 
There was an opposite case for factor e 
(conformational variation of ligand from 
optimum structure); forty-two FP points could 
be predicted. Such a result may be translated into 
the uncertainty of factor e in prediction of HIV-
1 PR targeted docking results and confirmed 
our previous results that inhibitors might not 
necessarily interact with the enzyme active site 
via their minimum energy conformation (18, 
19). This was also in agreement with our above 
analysis on binding factors i.e., significance 
percentage of 21.4% was estimated for factor e 
(Table 5). 
AutoDock binding affinities (factor a) 
and number of H-bond interactions (factor c) 
produced relatively balanced results (Figure 8). 
However analysis of docking results on the basis 
of hydrogen binding exhibited twenty-two non-
FP/FN points. It should be noted that most of the 
H-bond patterns showed reasonable agreement 
with the binding pattern of Amprenavir in its 
crystallographic file (IHPV).
Most of the Amprenavir conformations 
were predicted as FNs on the basis of lipophilic 
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interactions (seven FPs and thirty-seven FNs) 
but less non-FP/FNs were resulted (5 points).   
The outcomes of this study revealed that 
a major problem in docking based virtual 
screening is the proper selection of an enzyme 
conformation. Following this rationale and on 
the basis of results taken form ensemble docking 
approach, different scenarios may be considered: 
1) Docking validation (self-docking) 
protocols may be performed with less trouble 
due to the presence of induced target structure. 
2) Our ensemble docking approach on HIV-
1 PR system demonstrated that varied binding 
results might be expected upon docking of a 
specific inhibitor (Amprenavir) into the multiple 
conformations of the enzyme. To alleviate the 
problem, a simple docking approach within 
an enzyme including a similar cognate (co-
crystallographic) ligand (similar holo structure) 
followed by an efficient scoring function is 
proposed. 
3) In the case of holo enzyme structures 
bearing non-similar cognate ligands, an 
ensemble docking approach may be run by the 
cross-docking of a co-crystallographic enzyme 
inhibitor into the multiple enzyme structures 
(holo dataset). Subsequent analysis of probable 
induced fit determinants (section 3.1) may be 
done within the results of ensemble docking 
approach. Ranked induced fit determinants 
could be used in post-scoring of the ensemble 
docking results. 
4) When no holo structure is available, an 
ensemble docking approach may be run through 
apo structures of the enzyme.  
Conclusion
Computer aided molecular design (CAMD) 
has spurred a renewed interest to deal with the 
growing body of information from genomic 
and proteomic efforts. In this regard, molecular 
docking is an attractive branch of CAMD that 
allows drug designers to simulate binding mode 
and predict binding affinity of different ligand-
receptor complexes. In the present study, ensemble 
docking approach was successfully applied for 
modeling of anti-AIDS agent Amprenavir in the 
active site of HIV-1 PR. The outcomes of this 
study showed that success of a typical HIV-1 
PR targeted docking strategy in rational drug 
design might be strictly depended on a selection 
of docked enzyme conformation. Further results 
showed that in selection of a desirable HIV-1 PR 
target for docking of amprenavir like ligands, 
lipophilic contacts are very important while 
the effect of ligand departure from its optimum 
conformation is less important. Pertaining to 
this, the multiple-receptors docking approach 
might be a suitable strategy to find a relatively 
optimum conformation of the enzyme to run the 
docking simulation of a query class of inhibitors. 
It is apparently known that our analysis method 
might be biased due to the restricted dataset 
of crystallographic files, but retrieved protein 
conformations (PDB database) can be regarded 
as valuable sources of such studies since they 
represent real induced enzyme conformations 
upon binding to the assayed inhibitors. 
Moreover; the results of ensemble docking 
approach may be complementary to molecular 
dynamics simulations and hence assist in finding 
optimum dynamic paths.
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